What have we learned after four randomized controlled trials on neoadjuvant chemotherapy for ovarian cancer?

Batista T.P.HENG-CHENG HSU2021-09-272021-09-2720211048-891Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85098282292&doi=10.1136%2fijgc-2020-002268&partnerID=40&md5=300717904ba706bf2cced1e9f264e0f1https://scholars.lib.ntu.edu.tw/handle/123456789/583770cytoreduction surgical procedures; ovarian neoplasms[SDGs]SDG3[SDGs]SDG5BRCA1 protein; BRCA2 protein; advanced cancer; aggression; cancer chemotherapy; cancer prognosis; cancer survival; comorbidity; cytoreductive surgery; emergency health service; female; gene mutation; human; multimodality cancer therapy; neoadjuvant chemotWhat have we learned after four randomized controlled trials on neoadjuvant chemotherapy for ovarian cancer?note10.1136/ijgc-2020-002268333614572-s2.0-85098282292